ScienceOpen:
research and publishing network
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
My ScienceOpen
Sign in
Register
Dashboard
Blog
About
Search
Advanced search
My ScienceOpen
Sign in
Register
Dashboard
Search
Search
Advanced search
For Publishers
Discovery
Metadata
Peer review
Hosting
Publishing
For Researchers
Join
Publish
Review
Collect
Blog
About
2
views
0
references
Top references
cited by
3
0 reviews
Review
0
comments
Comment
0
recommends
+1
Recommend
0
collections
Add to
0
shares
Share
Twitter
Sina Weibo
Facebook
Email
1,115
similar
All similar
Record
: found
Abstract
: not found
Article
: not found
Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance
Author(s):
Alberto Arribas
,
Sara Napoli
,
Eugenio Gaudio
,
Luciano Cascione
,
Alessandra Di Veroli
,
Chiara Tarantelli
,
Filippo Spriano
,
Antonella Zucchetto
,
Francesca Rossi
,
Andrea Rinaldi
,
Anastasios Stathis
,
Georg Stuessi
,
Valter Gattei
,
Gabriele Cruciani
,
Emanuele Zucca
,
Davide Rossi
,
Francesco Bertoni
,
AJ Arribas
,
S. Napoli
,
E Gaudio
,
A. S. Arribas
,
L. Cascione
,
A. Di Veroli
,
C. Tarantelli
,
F Spriano
,
A. Zucchetto
,
F. de ROSSI
,
A. RINALDI
,
A Stathis
,
G. Stuessi
,
V Gattei
,
G Cruciani
,
E ZUCCA
,
D. ROSSI
,
F. BERTONI
Publication date:
2019
Journal:
Blood
Read this article at
ScienceOpen
Publisher
Further versions
Bookmark
There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.
Related collections
Exponential Random Graph Models
Author and article information
Journal
DOI::
10.1182/blood-2019-124299
Data availability:
Comments
Comment on this article
Sign in to comment
Related Documents Log
scite_
Similar content
1,115
(VEN) monotherapy for patients with chronic lymphocytic leukemia (CLL) who relapsed after or were refractory to Ibrutinib or Idelalisib
Authors:
J. JONES
,
MY Choi
,
AR Mato
…
Long-Term Follow-up of a Phase 1 Trial of Idelalisib (ZYDELIG®) in Combination with Bendamustine (B), Bendamustine/Rituximab (BR), Fludarabine (F), Chlorambucil (Chl), or Chlorambucil/Rituximab (ChlR) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Authors:
JC Barrientos
,
SE Coutre
,
SW de Laat
…
Idelalisib is effective in patients with high-risk follicular lymphoma and early relapse after initial chemoimmunotherapy
Authors:
AK Gopal
See all similar
Cited by
3
Pyrrolo[2′,3′:3,4]cyclohepta[1,2- d ][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types
Authors:
Virginia Spanò
,
Roberta Rocca
,
Marilia Barreca
…
Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond
Authors:
Jennifer K Lue
,
Owen A. O’Connor
,
Francesco Bertoni
Targeting IRAK4 with Emavusertib in Lymphoma Models with Secondary Resistance to PI3K and BTK Inhibitors
Authors:
Francesca Guidetti
,
Alberto J. Arribas
,
Giulio Sartori
…
See all cited by